NDATOPICALSOLUTION
Approved
Jun 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVAGARD is a topical antimicrobial solution combining chlorhexidine gluconate and alcohol for skin antisepsis. It is indicated for preoperative skin preparation and healthcare worker hand hygiene to reduce microbial load on skin surfaces. The formulation leverages the broad-spectrum antimicrobial activity of chlorhexidine combined with the rapid action of alcohol.
LOE Approaching
As LOE approaches, the brand team is likely consolidating headcount and shifting focus toward defensive positioning against generic and OTC competitors in the antiseptic market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AVAGARD represents a stable but declining asset with limited new opportunity; career progression depends on defensive brand strategy and operational efficiency in a commodity market. Professionals joining this team should expect a focus on customer retention, cost management, and market access rather than growth-stage innovation or expansion.
Brand ManagerProduct Manager
Worked on AVAGARD at Solventum? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.